In this review, we discuss the use of oncolytic viruses in cancer immunotherapy treatments in
general, with a particular focus on adenoviruses. These serve as a model to elucidate how …

Immuno-oncology (IO) has been an active area of oncology research. Following US FDA
approval of the first immune checkpoint inhibitor (ICI), ipilimumab (human IgG1 k anti-CTLA …

ABSTRACT On 2015, October 27th, the US Food and Drug Administration (FDA) has
officially approved talimogene laherparepvec (T-VEC, also known as OncoVEXGM-CSF) for …

Background We conducted a phase I study with a granulocyte macrophage colony
stimulating factor (GMCSF)-expressing oncolytic adenovirus, ONCOS-102, in patients with …

Advances in the understanding of cancer immunotherapy and the development of multiple
checkpoint inhibitors have dramatically changed the current landscape of cancer treatment …

Immunotherapy has recently garnered success with the induction of clinical responses in
tumors, which are traditionally associated with poor outcomes. Chimeric antigen receptor T …

Adenoviruses are a commonly utilized virus for gene therapy platforms worldwide. Since
adenovirus components are characterized as highly immunogenic, their immunogenicity …

Oncolytic virotherapy relies on the administration of non-pathogenic viral strains that
selectively infect and kill malignant cells while favoring the elicitation of a therapeutically …

Standard of care for cancer is commonly a combination of surgery with radiotherapy or
chemoradiotherapy. However, in some advanced cancer patients this approach might still …

Oncolytic virotherapy represents an attractive option for the treatment of a variety of
aggressive or refractory tumors. While this therapy is effective at rapidly debulking directly …